about
Preclinical efficacy of the c-Met inhibitor CE-355621 in a U87 MG mouse xenograft model evaluated by 18F-FDG small-animal PET.The SUV and FLT PET: a tasty alphabet soup or a dog's breakfast?PET in lymphoma.The role of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with mycosis fungoidesCan Positron Emission Tomography and Computed Tomography Be a Substitute for Bone Marrow Biopsy in Detection of Bone Marrow Involvement in Patients with Hodgkin's or Non-Hodgkin's Lymphoma?Usefulness of F-18 FDG PET/CT in subcutaneous panniculitis-like T cell lymphoma: disease extent and treatment response evaluation.Does autologous transplantation directly increase the risk of secondary leukemia in lymphoma patients?PET and PET/CT for response evaluation in lymphoma: current practice and developments.Predictive value and diagnostic accuracy of F-18-fluoro-deoxy-glucose positron emission tomography treated grade 1 and 2 follicular lymphoma.PET/CT in oncology: for which tumours is it the reference standard?PET imaging for Treatment Response in CancerPrediction of outcome in pediatric Hodgkin lymphoma based on interpretation of (18)FDG-PET/CT according to ΔSUVmax, Deauville 5-point scale and IHP criteria.Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.Therapeutic evaluation and prognostic value of interim hybrid PET/CT with (18)F-FDG after three to four cycles of chemotherapy in non-Hodgkin's lymphoma.Predictive value of [¹⁸F]fluoro-2-deoxy-D-glucose positron emission tomography for clinical outcome in patients with relapsed/refractory diffuse large B-cell lymphoma prior to and after autologous stem cell transplant.Utility of sonographically guided biopsy in metabolically suspected recurrent lymphoma.Pediatric lymphoma: metabolic tumor burden as a quantitative index for treatment response evaluation.Early therapeutic response assessment by (18)FDG-positron emission tomography during chemotherapy in patients with diffuse large B-cell lymphoma: isolated residual positivity involving bone is not usually a predictor of subsequent treatment failure.Importance of [18F]fluorodeoxyglucose-positron emission tomography scanning for the monitoring of responses to immunotherapy in follicular lymphoma.How useful is PET/CT imaging in the management of post-transplant lymphoproliferative disease after liver transplantation?Diagnostic value of software-based image fusion of computed tomography and F18-FDG PET scans in patients with malignant lymphoma
P2860
Q34164758-9AC5BDBB-DD19-4C57-97A6-AB1C1D85A54EQ34622215-4392CBAF-D5FC-4AD4-A3A6-647BF1EF21ADQ35650641-47B72342-AF3B-4C69-ACBA-1AC25241328AQ35778465-6AC72EDB-D5C2-47F9-A174-D056B9E0ED8AQ36038881-35E0E03C-487E-4837-BFD5-0D92360F2EB6Q36611291-A2680659-D15C-4624-979E-8D31FC3DED0AQ36672691-7A9FB302-AF55-400E-BF2B-447572CF3B88Q36746441-34133044-5A84-4246-B2E6-54E499B78CADQ36911505-0B0CEE0E-C64C-4DE4-A433-802CD8E53167Q36963748-6691742C-ECD8-43C3-9954-72C153FBE118Q37465205-050620F9-5410-4CC4-ABEC-8C2CBBAF129DQ38663136-78E9771B-C14A-4116-9D20-A2E277670170Q43173266-1B5F414F-88CE-4115-8167-18B988B6FD55Q43741190-13B380C5-C17C-491C-A96B-A3F335F92DBAQ44841241-6B9DA17D-3349-4563-9A0E-F446F900B378Q46802085-C9249820-4CC2-47A1-A059-807B202513FDQ50997691-42DDDD75-B58B-46D1-BBC1-A8A6FA10C0D6Q53485736-4FA790BD-4036-4145-8E0F-F48809415BF0Q53497334-712AEC93-7092-4328-94E8-91A7C013C0A4Q53530315-705631DB-9711-475E-863A-78CF56A63E30Q57649798-1A096DD4-5496-4C48-8C6E-A9697022EF99
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Evaluation of therapy for lymphoma.
@ast
Evaluation of therapy for lymphoma.
@en
type
label
Evaluation of therapy for lymphoma.
@ast
Evaluation of therapy for lymphoma.
@en
prefLabel
Evaluation of therapy for lymphoma.
@ast
Evaluation of therapy for lymphoma.
@en
P2093
P1476
Evaluation of therapy for lymphoma.
@en
P2093
Georges Fillet
Guy Jerusalem
Roland Hustinx
Yves Beguin
P304
P356
10.1053/J.SEMNUCLMED.2005.02.004
P577
2005-07-01T00:00:00Z